CADTH Canadian Drug Expert Committee recommendation. indication : treatment of neovascular (wet) age-related macular degeneration (nAMD). Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) :
Brolucizumab has a Health Canada indication for the treatment of nAMD. Brolucizumab is a humanized monoclonal single-chain Fv (scFv) antibody fragment directed against human VEGF. It is available as a single-use pre-filled syringe for intravitreal injection and the Health Canada-approved dose is 6...
Saved in:
| Online Access: |
Full text |
|---|---|
| Corporate Author: | |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2020
|
| Edition: | Version: 1. |
| Series: | Common drug review clinical review report.
|
| Subjects: |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | p2598181 | ||
| 005 | 20240206154745.0 | ||
| 006 | m o d | ||
| 007 | cr bn |||||||| | ||
| 008 | 210102s2020 onc o 000 0 eng | ||
| 035 | |a (DNLM)BKSHLF:NBK565314 | ||
| 035 | |a 101774933 | ||
| 035 | |a 1774933 | ||
| 040 | |a DNLM |b eng |e rda |c DNLM |d UtOrBLW | ||
| 041 | 0 | |a eng | |
| 042 | |a pcc | ||
| 043 | |a n-cn--- | ||
| 060 | 0 | 0 | |a WW 270 |
| 110 | 2 | |a CADTH Canadian Drug Expert Committee, |e author. |0 n 2019180882 | |
| 245 | 1 | 0 | |a CADTH Canadian Drug Expert Committee recommendation. |p Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) : |b indication : treatment of neovascular (wet) age-related macular degeneration (nAMD). |
| 246 | 1 | |a Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) | |
| 250 | |a Version: 1. | ||
| 264 | 1 | |a Ottawa (ON) : |b Canadian Agency for Drugs and Technologies in Health, |c May 2020. | |
| 300 | |a 1 online resource (1 PDF file (8 pages)). | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a CADTH common drug review | |
| 500 | |a "Final." | ||
| 520 | 3 | |a Brolucizumab has a Health Canada indication for the treatment of nAMD. Brolucizumab is a humanized monoclonal single-chain Fv (scFv) antibody fragment directed against human VEGF. It is available as a single-use pre-filled syringe for intravitreal injection and the Health Canada-approved dose is 6 mg (0.05 mL) administered by intravitreal injection every four weeks for the first three doses, after which it can be given as one injection every 12 weeks in patients without disease activity or one injection every eight weeks in patients with disease activity, based on the physician assessment. | |
| 536 | |a Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec. | ||
| 588 | |a Description based on online resource; title from PDF title page (viewed May 11, 2021). | ||
| 650 | 1 | 2 | |a Wet Macular Degeneration |x drug therapy. |0 D057135Q000188 |
| 650 | 2 | 2 | |a Antibodies, Monoclonal, Humanized. |0 D061067 |
| 650 | 2 | 2 | |a Cost-Benefit Analysis. |0 D003362 |
| 650 | 2 | 2 | |a Insurance, Health, Reimbursement. |0 D007349 |
| 651 | 2 | |a Canada. |0 D002170 | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e issuing body. |0 n 2007182676 | |
| 830 | 0 | |a Common drug review clinical review report. |0 n 2014186107 | |
| 951 | |a 2598181 | ||
| 998 | |a BKSHLF |b 20210102 | ||
| 999 | f | f | |i eb6a7b65-d4a7-5c00-8e6c-2265fb4d8957 |s 4dac7c01-3cd2-5b73-b3eb-f7723ee84916 |t 0 |
| 952 | f | f | |a Massachusetts College of Pharmacy and Health Sciences |b Online |c Online |d E-Collections |t 0 |e NCBI |h Other scheme |
| 856 | 4 | 0 | |t 0 |u http://www.ncbi.nlm.nih.gov/books/NBK565314/ |y Full text |
